Poster Session 4
Ellen M. Murrin, DO (she/her/hers)
Maternal Fetal Medicine Fellow
Inova Fairfax Medical Campus
Falls Church, VA, United States
Olivia LeBeau, MD
Resident
Inova Fairfax Medical Campus
Fairfax, Virginia, United States
Lillian Singer, MD
Resident
Inova Fairfax Medical Campus
Fairfax, Virginia, United States
Mark Kassab, DO
Resident
Inova Fairfax Medical Campus
Fairfax, Virginia, United States
Peyton Kalan
Inova Fairfax Medical Campus
Fairfax, Virginia, United States
McKenna Stidham, BS
University of Virginia College of Medicine
Charlottesville, Virginia, United States
Scott Sullivan, MD, MSCR
Director of Maternal Fetal Medicine
Inova Fairfax Medical Campus
Fairfax, Virginia, United States
G. Larry Maxwell, MD
President of Inova Women's Service Line
Inova Fairfax Medical Campus
Fairfax, Virginia, United States
George R. Saade, MD (he/him/his)
Professor and Chair, Associate Dean for Women's Health Obstetrics and Gynecology
Macon & Joan Brock Virginia Health Sciences Eastern Virginia Medical School at Old Dominion University
Norfolk, Virginia, United States
Antonio F. Saad, MBA, MD (he/him/his)
Director of Perinatal Research Unit, MFM Fellowship Program Director
Inova Health
Falls Church, Virginia, United States
To evaluate the efficacy and timing of intravenous (IV) iron therapy in improving hemoglobin (Hgb) levels and maternal and neonatal outcomes in pregnant women with iron-deficiency anemia (IDA).
Study Design:
A retrospective cohort study was conducted on pregnant women with IDA who received outpatient IV iron therapy from January 2017- June 2024. Patients were divided into those who received their last IV iron dose >10 days (N=331) or < 10 days (N=82) before delivery. Primary outcomes included changes in Hgb levels, maternal composite outcomes (including postpartum hemorrhage and blood transfusion), and neonatal outcomes (such as NICU admission and low birth weight).
Results: Demographics and characteristics did not differ between groups. The type of IV iron used was primarily iron sucrose ( >86.31%). The >10 days group showed a greater increase in Hgb levels post-infusion, with a median increase of 2.5 g/dL compared to 1.8 g/dL in the < 10 days group (p < 0.001). The maternal composite outcome rate was significantly lower in the >10 days group (7.14% vs. 14.63%, p=0.03). Neonatal outcomes, including NICU admissions (7.46% vs. 8.54%, p=0.7) and low birth weight (3.97% vs. 1.61%, p=0.4), did not differ between the groups.
Conclusion: IV iron therapy improves hemoglobin levels in antenatal IDA. Administering the last dose of IV iron more than 10 days before delivery is associated with better maternal outcomes, suggesting that earlier treatment may reduce the risk of adverse pregnancy outcomes. Further studies are needed to refine treatment protocols and timing of administration to maximize benefits.
